A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

Study Overview

This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.

Study Description

The purpose of this study is to assess whether continuation of pembrolizumab in combination with next-line chemotherapy will prolong progression free survival by RECIST 1.1 criteria in patients who previously benefitted from a PD-1/PD-L1 inhibitor but now have progressive disease as compared to historical controls.

Additional Information:

Participants will not be paid for their participation.

Research Study Identifier: TX7499
ClinicalTrials.gov Identifier: NCT1701894485 (BTCRCLUN15-029)
Principal Investigator: Greg Durm, MD

Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.